Psychedelic Medicine Media Articles
Below are key excerpts of inspiring news articles on psychedelic medicine from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.
The psychoactive drug known as ecstasy can make people feel extra loving toward others. A study published Thursday suggests it has the same effect on octopuses. Octopuses are almost entirely antisocial, except when they're mating. Scientists who study them have to house them separately so they don't kill or eat each other. However, octopuses given the drug known as MDMA (or ecstasy, E, Molly or a number of other slang terms) wanted to spend more time close to other octopuses and even hugged them. Octopuses' ... brains have a host of strange structures that evolved on a completely different trajectory from the human path. "They have this huge complex brain that ... has absolutely no business acting like ours does but here they show that it does," says [neuroscientist Judit] Pungor. "This ... gentle, cuddly behavior is really pretty fascinating." The idea to test the drug's effect in octopuses came from Gul Dolen, a neuroscientist at Johns Hopkins University. "My lab has been studying MDMA for a long time, she says, "and we have worked out a lot of neural mechanisms that enable MDMA to have ... pro-social effects." Dolen got interested in octopuses a few years ago, when scientists sequenced the full genetic code of a ... California two-spot octopus. It turns out that octopuses and people have almost identical genes for a protein that binds the signaling molecule serotonin to brain cells. This protein is also the target of MDMA, so Dolen wondered how the drug would affect this usually unfriendly animal.
Note: Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.
It's the little things that Jon Lubecky appreciates now, like playing a board game with his family. But it wasn't always that way for the former Army sniper, who came home in 2006 after nearly a year in Iraq with a traumatic brain injury from a mortar attack and a nasty case of post-traumatic stress disorder (PTSD). Traditional treatments, including the use of antidepressants like Zoloft, were useless. Over three sessions, Lubecky spent six to eight hours under the influence of MDMA, the active ingredient in ecstasy. Finally, Lubecky was able to talk about his trauma and thus make progress dealing with it. Rick Doblin runs the Multidisciplinary Association for Psychedelic Studies, or MAPS, a non-profit advocating for MDMA-assisted psychotherapy. "It starts by reducing activity in the amygdala, which is the fear-processing part of the brain, so that people's fearful emotions linked to trauma can be more easily recalled and processed," Doblin said. Once the drug produces feelings of safety, veterans can then access memories which had been crippling before. While one in three veterans found pills like Zoloft and Paxil effective in treating their PTSD, a study including 24 veterans showed PTSD was eliminated in 68 percent of vets treated with MDMA-assisted therapy and significantly reduced in the other 32 percent. MDMA-assisted therapy is now about to begin its third phase of FDA testing. If all goes well, MDMA will be available by prescription as early as 2021.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs.
Recreational marijuana use will soon be legal in Canada after the Senate passed a "historic" bill. Canada is only the second country in the world - and the first G7 nation - to implement legislation to permit a nationwide marijuana market. In the neighboring US, nine states and the District of Columbia now allow for recreational marijuana use, and 30 allow for medical use. The Cannabis Act, stems from a campaign pledge of Prime Minister Justin Trudeau to keep marijuana away from underage users and reduce related crime. Uruguay was the first country to legalize marijuana's production, sale and consumption in December 2013. The justice minister, Jody Wilson-Raybould, ... applauded the vote. "This is an historic milestone for progressive policy in Canada," she tweeted. "This legislation will help protect our youth from the risks of cannabis while keeping profits out of the hands of criminals and organized crime." Once the bill is formally approved, adults will be able to carry and share up to 30 grams of legal marijuana in public. They also will be allowed to cultivate up to four plants in their households. However, stringent rules will still govern the purchase and use of marijuana. Consumers are expected to purchase marijuana from [regulated] retailers. Marijuana will also not be sold in the same location as alcohol or tobacco. The Canadian government has also implemented changes to their impaired driving laws, to address repercussions for driving under the influence of cannabis.
Note: In the US, more people are arrested for marijuana use than for all violent crimes combined.
It was only after U.S. veteran Jonathan Lubecky pulled the trigger on a loaded gun aimed at his head and it misfired that he finally decided to seek help. He had tried to commit suicide five times after struggling with post-traumatic stress disorder (PTSD). The only two drugs approved by the Food and Drug Administration for PTSD, Zoloft and Paxil ... didnt work for combat-related PTSD. Out of desperation, he volunteered as a subject in an experimental study of MDMA-assisted psychotherapy for chronic, treatment-resistant PTSD. The study was sponsored by the ... Multidisciplinary Association for Psychedelic Studies (MAPS), and funded entirely by private donations. After his treatment with MDMA-assisted psychotherapy, Lubecky managed to heal from his PTSD to the point that he became National Veterans Director for Senator Rand Pauls 2016 presidential primary campaign. His recovery is not unusual. The Lancet Psychiatry published a scientific paper about the study Lubecky volunteered for; it reported that two-thirds of the 26 veterans, firefighters and police officers treated no longer qualified for a diagnosis of PTSD one month after their second MDMA session, with their reduction of PTSD symptoms lasting over time. Drug prohibition has for decades delayed medical research into the healing properties of Schedule 1 drugs. Now that this research is finally being conducted, were learning that enormous suffering and many suicides could have been prevented over these decades.
Note: The above was written by MAPS founder Rick Doblin. Read more about how MDMA, also known as 'ecstasy,' has been found to be effective for treating PTSD in a therapeutic context. Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream scientific credibility.
To microdose is to take small amounts of LSD, which generate subperceptual effects that can improve mood, productivity and creativity. Michael Pollans new book, How to Change Your Mind, is not about that. Its about taking enough LSD or psilocybin (mushrooms) to feel the colors and smell the sounds. If Pollans wide-ranging account has a central thesis, its that were still doing the hard work of rescuing the science of psychedelics from the countercultural baggage of the 1960s. In the mid-60s the exuberance surrounding these new drugs gave way to moral panic, and ... the whole project of psychedelic science had collapsed. Before collapsing, though, that project discovered in psychedelics the same potential that scientists are exploring as they reclaim it today: possible help in treating addiction, anxiety and depression, and existential distress common in people confronting a terminal diagnosis, which of course, broadly speaking, is all of us. Pollan doesnt give a lot of prime real estate to psychedelics naysayers. But given that those on LSD can appear to be losing their minds, and that the drug leaves one feeling emotionally undefended (a potential benefit as well as a profound risk), he does strongly recommend having an experienced guide in a proper setting when you trip. With those safeguards in place, he believes usage could be on the verge of more widespread acceptance.
Note: A recent clinical trial found psilocybin to be an extremely effective treatment for anxiety and depression. Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream credibility.
Recent trials of psilocybin, a close pharmacological cousin to LSD, have demonstrated that a single guided psychedelic session can alleviate depression when drugs like Prozac have failed; can help alcoholics and smokers to break the grip of a lifelong habit; and can help cancer patients deal with their existential distress at the prospect of dying. At the same time, studies imaging the brains of people on psychedelics have opened a new window onto the study of consciousness, as well as the nature of the self and spiritual experience. Perhaps the most significant new evidence for the therapeutic value of psychedelics arrived in a pair of phase 2 trials (conducted at Johns Hopkins and NYU and published in the Journal of Psychopharmacology in 2016) in which a single high dose of psilocybin was administered to cancer patients struggling with depression, anxiety and the fear of death or recurrence. Eighty percent of the Hopkins cancer patients who received psilocybin showed clinically significant reductions in standard measures of anxiety and depression, an effect that endured for at least six months after their session. Results at NYU were similar. Curiously, the degree to which symptoms decreased in both trials correlated with the intensity of the mystical experience that volunteers reported, a common occurrence during a high-dose psychedelic session. Few if any psychiatric interventions for anxiety and depression have ever demonstrated such dramatic and sustained results.
Note: This entire article by best-selling author Michael Pollan is filled with the results of excellent studies in this exciting new field. If the above link fails, here is an alternative link. Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream scientific credibility.
MDMA - the active ingredient in the banned street drug ecstasy - is safe and enhances the treatment of post-traumatic stress disorder when administered during psychotherapy, according to a new clinical trial. The US Food and Drug Administration-approved ... study included just 26 patients, all of them veterans, firefighters and police officers who developed PTSD as a result of trauma in the line of duty. PTSD ... affects about 8 million American in any given year. Continuing symptoms, including flashbacks and frightening thoughts, may lead to substance abuse, unemployment, family disruption and even suicide. Up to 72% of veterans who receive psychotherapy retain their PTSD diagnosis and frequently drop out of their treatment programs. "We only included people who had received prior treatment but still had clinically significant PTSD," [Dr. Michael C. Mithoefer, lead author of the study] said. Participants received ... about 13 hours of non-drug psychotherapy plus two eight-hour sessions of MDMA-assisted psychotherapy. Participants were randomly assigned to receive MDMA (orally) in one dose of either 30, 75 or 125 milligrams for each of the two MDMA-assisted psychotherapy sessions. One month after the second MDMA session, 68% of patients in the two higher-dose groups no longer qualified for a diagnosis of PTSD. One year later, 67% of all participants no longer qualified for a diagnosis of PTSD. Those participants who still met the criteria for PTSD experienced a reduction in symptoms, the researchers noted.
Note: Watch an engaging interview with one of the participants of the study at the link above. Read more about how MDMA has been found to be effective for treating PTSD in a therapeutic context. Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream scientific credibility.
As more states legalize marijuana, there's growing interest in a cannabis extract cannabidiol, also known as CBD. It's marketed as a compound that can help relieve anxiety - and, perhaps, help ease aches and pains, too. CBD doesn't have the same mind-altering effects as marijuana, since it does not contain THC, the psychoactive component of the plant. "There's good evidence to suggest that CBD could be an effective treatment of anxiety and addiction" and other disorders, says Dr. Esther Blessing, a psychiatrist and researcher at New York University. "But we need clinical trials." Small, short-term human studies ... suggest CBD exhibits anti-inflammatory and anti-anxiety properties. These preliminary findings piqued Blessing's interest. For instance, she points to a 2011 study of a few dozen people, some of whom had social anxiety disorder, who were asked to speak in front of a large audience. Researchers compared anxiety levels in people after they took CBD, compared to those who got the placebo or nothing at all. "People who took CBD reported significantly less anxiety" compared to those who got the placebo, Blessing says. Though CBD supplements are widely available for sale, a legal murkiness surrounds marijuana extracts. Even if you live in a state where marijuana use is legal, the federal Drug Enforcement Administration still classifies the CBD extract as a Schedule 1 substance the DEA's most restricted category.
Note: Read more about the use of CBD to treat epilepsy and other serious conditions. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources.
In recent years, rigorous research has been conducted on entheogens, such as ayahuasca, LSD, mescaline and psilocybin, and on the empathogen Ecstasy. The goal is to evaluate their effects on addiction, cluster headaches, depression, trauma, cancer, epilepsy, death and dying, as well as to explore their value in the study of consciousness. Psilocybin - or magic mushrooms - have been used in traditional healing rituals for thousands of years. However, for more than 40 years it has been illegal in the U.S. But recent findings are tearing down the barriers surrounding psychedelic research, as it has been clinically shown that they have the ability to ease depression and soothe anxiety in patients dealing with serious illness and impending death. Two separate studies discovered that a single, moderate-to-large dose of psilocybin was able to help alleviate profound distress among cancer patients. Researchers know how, but they do not know why, psilocybin has worked in these settings. One theory is that psilocybin interrupts the circuitry of self-absorbed thinking that is so pronounced in depressed people, making way for a mystical experience. Neuro-imaging studies ... suggest that the positive effects of psychedelic-assisted psychotherapy are explained by changes in something in the brain called the default mode network. It turns out that this network is hyperactive in depression. Interestingly, in both meditation and also with psilocybin this network becomes quiescent.
Note: See an article in the UK's Independent showing remarkable results from these studies. Learn more about the healing potentials of mind-altering drugs now being explored by the scientific community.
According to one theory, jolly old St. Nick might have been so jolly because he was derived from shamans who went from hut to hut handing out hallucinatory mushrooms in Siberia and the Arctic during the Winter Solstice, right around the same time as Christmas. "As the story goes, up until a few hundred years ago these practicing shamans or priests connected to the older traditions would collect Amanita muscaria (the Holy Mushroom), dry them, and then give them as gifts on the winter solstice," [said] anthropologist John Rush. The festive deep red and white mushrooms were eaten by the humans and reindeer who roamed the region, sending both of them on well ... a tinsel-turvy trip. "This idea [is] that reindeer go berserk because they're eating Amanita muscaria. Reindeers flying are they flying, or are your senses telling you they're flying because you're hallucinating?" Harvard biology professor Donald Pfister told NPR. Reindeer were also considered "spirit animals" and the Siberian shamans wore red deer pelts as tributes, according to scholars. Even more, shamans dressed up like the mushrooms, which explains Santa's cozy red and white suit. Another scholar told NBC that the idea of Rudolph's flashy red nose likely originated from the color of the mushrooms, noting how remarkable it was that the tripping beast was put in charge of directions. "It's amazing that a reindeer with a red-mushroom nose is at the head, leading the others," Boston College classics professor Carl Ruck mused.
Note: See a 7-minute New York Times video on this intriguing hypothesis. For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
After months of deliberation and investigation, the WHO has concluded that cannabidiol (CBD) is a useful treatment for epilepsy and palliative care, and does not carry any addiction risks. The organization is set to run a fuller review of cannabis next year. The report ... also recommended imposing the strong restrictions available on fentanyl, a synthetic opioid which has killed thousands of people in Americas drug addiction epidemic. There is increased interest from Member States in the use of cannabis for medical indications including for palliative care, the report said. Responding to that interest and increase in use, WHO has in recent years gathered more robust scientific evidence on therapeutic use and side effects of cannabis and cannabis components. In conclusion, the authors wrote: Recent evidence from animal and human studies shows that its use could have some therapeutic value for seizures due to epilepsy and related conditions. They added that current information does not justify scheduling of cannabidiol, and declared that taking medical marijuana will not lead to addiction to THC, the psychoactive property of cannabis that induces a high.
Note: More people are arrested in the US for marijuana use than for all violent crimes combined and the US federal government continues to regard non-psychoactive CBD as a dangerous drug. The UK government recently announced it will regulate CBD as medicine. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources.
When the drugs came, they hit all at once. It was the 80s, and by the time one in 10 people had slipped into the depths of heroin use - bankers, university students, carpenters, socialites, miners - Portugal was in a state of panic. In 2001 ... Portugal became the first country to decriminalise the possession and consumption of all illicit substances. Rather than being arrested, those caught with a personal supply might be given a warning, a small fine, or told to appear before a local commission a doctor, a lawyer and a social worker about treatment, harm reduction, and the support services that were available to them. The opioid crisis soon stabilised, and the ensuing years saw dramatic drops in problematic drug use, HIV and hepatitis infection rates, overdose deaths, drug-related crime and incarceration rates. HIV infection plummeted from an all-time high in 2000 of 104.2 new cases per million to 4.2 cases per million in 2015. Portugals remarkable recovery ... could not have happened without an enormous cultural shift, and a change in how the country viewed drugs. Portugals policy rests on three pillars: one, that theres no such thing as a soft or hard drug, only healthy and unhealthy relationships with drugs; two, that an individuals unhealthy relationship with drugs often conceals frayed relationships with loved ones, with the world around them, and with themselves; and three, that the eradication of all drugs is an impossible goal. In spite of Portugals tangible results, other countries have been reluctant to follow.
Note: Portugal's successful policy has contributed to public health outcomes that starkly contrast US trends.
Against the backdrop of the nation's largest Veterans Day parade, Democratic Gov. Andrew Cuomo announced this month he'd sign legislation making New York the latest in a fast-rising tide of states to OK therapeutic pot as a PTSD treatment, though it's illegal under federal law. Twenty-eight states plus the District of Columbia now include PTSD in their medical marijuana programs, a tally that has more than doubled in the last two years. The increase has come amid increasingly visible advocacy from veterans' groups. Retired Marine staff sergeant Mark DiPasquale says the drug freed him from the 17 opioids, anti-anxiety pills and other medications that were prescribed to him for migraines, post-traumatic stress and other injuries from service that included a hard helicopter landing in Iraq in 2005. In a sign of how much the issue has taken hold among veterans, the 2.2-million-member American Legion began pressing the federal government this summer to let Department of Veterans Affairs doctors recommend medical marijuana where it's legal. The Legion started advocating last year for easing federal constraints on medical pot research, a departure into drug policy for the nearly century-old organization. "People ask, `Aren't you the law-and-order group?' Why, yes, we are," Executive Director Verna Jones said at a Legion-arranged news conference early this month at the U.S. Capitol. But "when veterans come to us and say a particular treatment is working for them, we owe it to them to listen and to do scientific research required."
Note: This Associated Press article no longer appears on CNBC's website. Here's an alternate link for the complete article. The illegal drug MDMA was recently fast tracked for FDA approval after preliminary studies found it to be effective for treating PTSD in a therapeutic context. While police in the US arrest more people for marijuana use than for all violent crimes combined, articles like these suggest that the healing potentials of mind-altering drugs are gaining mainstream credibility.
In July, the Food and Drug Administration took the important step of approving two final-phase clinical trials to determine whether a party drug that has long been on the Drug Enforcement Administrations Schedule I list of banned substances could be used to treat a psychiatric condition that afflicts millions. The drug is MDMA, a psychedelic commonly known as Ecstasy. The trials aim to determine whether the drug is, as earlier trials have suggested, a safe and effective treatment for post-traumatic stress disorder. The F.D.A. approval is a beacon of hope for the roughly eight million Americans believed to suffer from PTSD, a group that includes victims of abuse, refugees and combat veterans. The shortcomings in the way we have typically treated PTSD mean that many are condemned to suffer from the condition for years, even decades, with little relief. Less than 20 percent of patients are estimated to get effective treatment through prescription psychiatric drugs ... which, along with psychotherapy, have been the global standard of mental health care since the 1990s. This could change with the F.D.A.s decision, which has given MDMA-assisted psychotherapy for the treatment of PTSD the status of a potential breakthrough therapy. This designation permits the fast-tracking of trials in hopes of proving the drug, which has psychedelic and stimulant effects, to be safe and capable of doing what no other drug on the market can.
Note: Read more about how MDMA has been found to be highly effective for treating PTSD in a therapeutic context. Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream scientific credibility.
Stephen Ross spends most of his time helping people quit drugs. But early next year, he will begin administering MDMA in his ... medical research lab. MDMA, aka ecstasy, will still be an illegal drug. But its emerging as one of the most promising treatments for intractable post-traumatic stress disorder. Rick Doblin ... encountered MDMA for the first time [in 1982]. Two years later, he watched a patient suffering from PTSD undergo MDMA-assisted therapy. That completely persuaded me of its therapeutic potential, Doblin says. In 1985, Doblin learned that the DEA was moving to ban the drug ... and founded a nonprofit - the Multidisciplinary Association for Psychedelic Studies - to fight the prohibition. In 2000 [Doblin] met Michael Mithoefer, a therapist specializing in PTSD. Mithoefer had grown frustrated by the available treatments. Mithoefer and his wife and co-therapist, Annie, conducted the first MAPS-funded Phase II trial in 2004, which used MDMA to treat PTSD in victims of rape and childhood sexual abuse. These were patients with chronic cases that had proved resistant to other treatment methods. A second group, made up of veterans, firefighters and police officers, followed. Therapists refer to MDMA as an empathogen - something that enables patients to feel empathy not just for others but also for themselves. Of the 90 people who completed the 12-month follow-up after Phase II, 68% of them did not meet PTSD criteria, according to the study results MAPS submitted to the FDA. Of the remaining third, many had some reduction in symptoms.
Note: Read more about how MDMA has been found effective for treating PTSD in a therapeutic context. Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream scientific credibility.
A nascent movement of activists working to reframe psilocybin as both a medicine and as a tool for personal or spiritual growth [thinks] researchers and policy makers should be able to discuss, in a dispassionate way, the medical or recreational use of hallucinogenic drugs a subject that not long ago was unthinkable. The Boston Entheogenic Network (BEN) ... formed last year. Instead of the more familiar, more polarizing adjective psychedelic, BEN uses the term entheogenic - meaning generating the divine within - to describe multiple methods of achieving altered states of consciousness. Proof of medical usefulness was the first step toward marijuanas legalization. Could it be the same for hallucinogens? In fact, medical applications for psilocybin abound. Recent studies have found that MDMA seems to be a remarkably useful tool in treating post-traumatic stress disorder, when combined with psychotherapy. In August, the FDA designated the drug as a breakthrough therapy, meaning that it may have substantial advantages over existing PTSD treatments. Other studies suggest psilocybin has promise as a treatment for anxiety and depression. Meanwhile, microdosing - the regular use of tiny amounts of LSD or other psychedelics not to hallucinate but to improve creativity and mood - has become a Silicon Valley trend. Advocates for psychedelics have come a long way from Learys indiscriminate call for young people to turn on, tune in, and drop out, but many still believe these drugs could change the world.
Note: Read more about how MDMA has been found effective for treating PTSD in a therapeutic context. Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream scientific credibility.
In the mid-1950s, LSD and other psychedelic drugs took the medical world by storm. Studies at the time suggested that the hallucinogens were effective against a variety of difficult-to-treat mental health problems. The research stalled in the early 1970s ... but [it] is picking up again. If the drugs prove to be as safe and effective as recent research suggests, we may be on the brink of what some are calling a revolution in mental health care. People with mood disorders, including those who are unresponsive to conventional therapies, might be able to ditch their antidepressants and antianxiety medications. Those with terminal illness could enjoy their remaining days without the fear of death looming over them, while people with PTSD could return to a normal life unobstructed by paralyzing flashbacks. Were not at this point yet. But such is the promise of psychedelic medicine. What makes psychedelic therapy so powerful? Experts say it may be because the drugs work on a deep emotional as well as biological level, with patients experiencing a transformative sense of positivity, benevolence, and unity. "Unlike almost all other psychiatric medications ... these drugs seem to work through biology to open up a psychological opportunity," says Matthew Johnson, a Johns Hopkins University psychiatrist. And the drugs benefits may go beyond simply treating specific disorders. In 2011, Johnson and his colleagues showed that a single psilocybin session can give people a more "open" personality, as well as a greater appreciation of new experiences.
Note: Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream scientific credibility.
After years of lobbying and experimental research, the FDA has granted "breakthrough therapy" status for the drug MDMA as a potential treatment for post-traumatic stress disorder. The designation does not mean the drug is FDA-approved, but it does ease the way for clinical trials to test its safety and effectiveness in patients with PTSD. The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS), which has been advocating and fundraising for MDMA research for three decades, announced the FDA's designation. More commonly known as its street names ecstasy or Molly, MDMA (methylenedioxymethamphetamine) is a psychoactive drug that produces feelings of energy and euphoria, often followed by an emotional crash. In recent years, some in the scientific community have suggested it could have medical benefits, as well. In previous phases of clinical trials, the drug was shown to offer significant relief to sufferers of PTSD, a mental health disorder characterized by nightmares or flashbacks and heightened anxiety or depression after experiencing or witnessing a terrifying event. In phase 2 clinical trials sponsored by MAPS, 61 percent of the 107 participants with chronic, treatment-resistant PTSD no longer had the disorder after two months of MDMA-assisted psychotherapy treatment. At a 12-month follow up, 68 percent no longer had PTSD. The organization expects to begin phase 3 trials with a larger group of participants next year.
Note: For more along these lines, see concise summaries of deeply revealing news articles on mind-altering drugs from reliable major media sources.
For Jon Lubecky, the scars on his wrists are a reminder of the years he spent in mental purgatory. He returned from an Army deployment in Iraq a broken man. He got every treatment offered by Veterans Affairs for post-traumatic stress disorder. But they didnt stop him from trying to kill himself - five times. Finally, he signed up for an experimental therapy and was given a little green capsule. The anguish stopped. Inside that pill was the compound MDMA, better known ... as ecstasy. That street drug is emerging as the most promising tool in years for the militarys escalating PTSD epidemic. The MDMA program was created by a small group of psychedelic researchers who had toiled for years in the face of ridicule, funding shortages and skepticism. But the results have been so positive that this month the Food and Drug Administration deemed it a breakthrough therapy - setting it on a fast track for review and potential approval. Only two drugs are approved for treating PTSD: Zoloft and Paxil. Both have proved largely ineffective. By giving doses of MDMA at the beginning of three, eight-hour therapy sessions, researchers say they have helped chronic PTSD patients process and move past their traumas. In clinical trials with 107 patients closely monitored by the FDA, 61 percent reported major reductions in symptoms - to the point where they no longer fit the criteria for PTSD. Follow-up studies a year later found 67 percent no longer had PTSD.
Note: Read more about how MDMA has been found effective for treating PTSD in a therapeutic context. Articles like this suggest that the healing potentials of mind-altering drugs are gaining mainstream scientific credibility.
In the last few years, calls for marijuana to be researched as a medical therapy have increased. It may be time for us to consider the same for psychedelic drugs. Two general classes of such drugs exist, and they include LSD, psilocybin, mescaline and ecstasy (MDMA). All are illegal in the United States, [and can] cause harm. The best-known adverse event is persistent flashbacks, though these are believed to be rare. More common are symptoms like increased heart rate and blood pressure, anxiety and panic. Some people have pointed to ... positive effects. People with life-threatening illnesses can also suffer from anxiety, which is hard to treat. In 2014, a small randomized controlled trial was published that examined if LSD could be used to improve this anxiety. Anxiety was significantly reduced in the intervention group for up to a year. More common are studies of the use of psychedelics to treat abuse or addiction to other substances. [One study] exploring LSDs potential to treat alcoholism [found that] alcohol use and misuse were significantly reduced in the LSD group for six months. Similar studies using psilocybin have also shown promising results. Researchers [have also] examined the potential for MDMA in the treatment of chronic and treatment-resistant post-traumatic stress disorder. At two months after therapy, more than 80 percent of those in the treatment group saw a clinical improvement versus only 25 percent of those in the placebo group. The beneficial effects lasted for at least four years, even with no further treatment.
Note: Read more about how MDMA has been found effective for treating PTSD in a therapeutic context. Articles like this suggest that the healing potentials of mind-altering drugs are beginning to gain mainstream scientific credibility.
Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
